EF Hutton Acquisition Co. I assumed coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) in a report issued on Thursday, Benzinga reports. The brokerage issued a buy rating and a $25.00 target price on the biotechnology company's stock.
Separately, StockNews.com assumed coverage on Atara Biotherapeutics in a research report on Wednesday, October 12th. They issued a hold rating for the company. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Atara Biotherapeutics currently has an average rating of Hold and a consensus price target of $19.50.
Get
Atara Biotherapeutics alerts:
Atara Biotherapeutics Stock Performance
Shares of NASDAQ:ATRA opened at $3.50 on Thursday. Atara Biotherapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $16.44. The business has a 50-day simple moving average of $4.08 and a two-hundred day simple moving average of $4.44. The firm has a market cap of $332.08 million, a price-to-earnings ratio of -1.42 and a beta of 1.08.
Insider Buying and Selling at Atara Biotherapeutics
In other Atara Biotherapeutics news, CFO Utpal Koppikar sold 6,255 shares of the business's stock in a transaction dated Wednesday, November 16th. The stock was sold at an average price of $4.49, for a total transaction of $28,084.95. Following the completion of the sale, the chief financial officer now directly owns 191,334 shares in the company, valued at approximately $859,089.66. The transaction was disclosed in a filing with the SEC, which is available at
the SEC website. In other Atara Biotherapeutics news, CEO Pascal Touchon sold 15,591 shares of the business's stock in a transaction dated Wednesday, November 16th. The stock was sold at an average price of $4.49, for a total transaction of $70,003.59. Following the completion of the sale, the chief executive officer now directly owns 441,696 shares in the company, valued at approximately $1,983,215.04. The transaction was disclosed in a filing with the SEC, which is available at
the SEC website. Also, CFO Utpal Koppikar sold 6,255 shares of the business's stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $4.49, for a total value of $28,084.95. Following the transaction, the chief financial officer now owns 191,334 shares of the company's stock, valued at $859,089.66. The disclosure for this sale can be found
here. Insiders sold a total of 29,800 shares of company stock worth $133,802 in the last three months. 4.00% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its stake in shares of Atara Biotherapeutics by 117.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 642,158 shares of the biotechnology company's stock valued at $2,427,000 after acquiring an additional 347,261 shares during the period. Balyasny Asset Management LLC grew its stake in shares of Atara Biotherapeutics by 213.3% during the 3rd quarter. Balyasny Asset Management LLC now owns 58,472 shares of the biotechnology company's stock valued at $221,000 after acquiring an additional 39,806 shares during the period. BNP Paribas Arbitrage SNC grew its stake in shares of Atara Biotherapeutics by 637.5% during the 3rd quarter. BNP Paribas Arbitrage SNC now owns 198,267 shares of the biotechnology company's stock valued at $749,000 after acquiring an additional 171,382 shares during the period. Alliancebernstein L.P. grew its stake in shares of Atara Biotherapeutics by 43.4% during the 3rd quarter. Alliancebernstein L.P. now owns 107,040 shares of the biotechnology company's stock valued at $405,000 after acquiring an additional 32,400 shares during the period. Finally, State Street Corp grew its stake in shares of Atara Biotherapeutics by 30.1% during the 3rd quarter. State Street Corp now owns 8,097,353 shares of the biotechnology company's stock valued at $30,608,000 after acquiring an additional 1,875,667 shares during the period.
Atara Biotherapeutics Company Profile
(Get Rating)
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.
Recommended Stories
- Get a free copy of the StockNews.com research report on Atara Biotherapeutics (ATRA)
- Will LI Auto Be the Least Hated Chinese EV Stock in 2023?
- Which Streaming Service Stock is Best in 2023?
- Here's Why Snap Stock Can Double in 2023
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
